Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Ernexa’s stem cell therapy could soon enter ovarian cancer trials
- Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma
- Scientists find new way to kill treatment-resistant myeloma cells
- Phase 3 blood cancer vaccine trial moves toward final analysis
- Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
- MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma
- Phase 3 trial testing if oral pill can stop pancreatic cancer from returning
- (no title)
- Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
- CAR T-cells in multiple myeloma: the race to the start line